vs
Side-by-side financial comparison of Richmond Mutual Bancorporation, Inc. (RMBI) and Spero Therapeutics, Inc. (SPRO). Click either name above to swap in a different company.
Richmond Mutual Bancorporation, Inc. is the larger business by last-quarter revenue ($13.1M vs $12.6M, roughly 1.0× Spero Therapeutics, Inc.). Spero Therapeutics, Inc. runs the higher net margin — 250.7% vs 26.1%, a 224.6% gap on every dollar of revenue. On growth, Spero Therapeutics, Inc. posted the faster year-over-year revenue change (24080.8% vs 18.1%). Over the past eight quarters, Spero Therapeutics, Inc.'s revenue compounded faster (847.7% CAGR vs 9.1%).
Richmond Mutual Bancorporation, Inc. is a U.S.-based bank holding company operating primarily in Indiana. It offers a full range of personal and commercial banking solutions including deposit accounts, mortgage loans, small business lending, and wealth management services, serving local retail consumers and small-to-medium enterprise clients via its regional branch network.
RMBI vs SPRO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.1M | $12.6M |
| Net Profit | $3.4M | $31.5M |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | 26.1% | 250.7% |
| Revenue YoY | 18.1% | 24080.8% |
| Net Profit YoY | 37.7% | 250.9% |
| EPS (diluted) | $0.35 | $0.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.1M | $12.6M | ||
| Q3 25 | $12.6M | $0 | ||
| Q2 25 | $11.8M | $0 | ||
| Q1 25 | $11.4M | $12.0K | ||
| Q4 24 | $11.1M | $52.0K | ||
| Q3 24 | $10.8M | $65.0K | ||
| Q2 24 | $10.7M | $114.0K | ||
| Q1 24 | $11.0M | $140.0K |
| Q4 25 | $3.4M | $31.5M | ||
| Q3 25 | $3.6M | $-7.4M | ||
| Q2 25 | $2.6M | $-1.7M | ||
| Q1 25 | $2.0M | $-13.9M | ||
| Q4 24 | $2.5M | — | ||
| Q3 24 | $2.5M | $-17.1M | ||
| Q2 24 | $2.1M | $-17.9M | ||
| Q1 24 | $2.4M | $-12.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -122758.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -28604.6% | ||
| Q2 24 | — | -16720.2% | ||
| Q1 24 | — | -9987.1% |
| Q4 25 | 26.1% | 250.7% | ||
| Q3 25 | 28.6% | — | ||
| Q2 25 | 22.0% | — | ||
| Q1 25 | 17.2% | -115550.0% | ||
| Q4 24 | 22.4% | — | ||
| Q3 24 | 23.0% | -26380.0% | ||
| Q2 24 | 19.3% | -15668.4% | ||
| Q1 24 | 21.6% | -9049.3% |
| Q4 25 | $0.35 | $0.56 | ||
| Q3 25 | $0.36 | $-0.13 | ||
| Q2 25 | $0.26 | $-0.03 | ||
| Q1 25 | $0.20 | $-0.25 | ||
| Q4 24 | $0.25 | — | ||
| Q3 24 | $0.24 | $-0.32 | ||
| Q2 24 | $0.20 | $-0.33 | ||
| Q1 24 | $0.23 | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $33.1M | $40.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $145.8M | $59.0M |
| Total Assets | $1.5B | $68.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $33.1M | $40.3M | ||
| Q3 25 | $34.3M | $48.6M | ||
| Q2 25 | $27.2M | $31.2M | ||
| Q1 25 | $27.0M | $48.9M | ||
| Q4 24 | $21.8M | $52.9M | ||
| Q3 24 | $19.6M | $76.3M | ||
| Q2 24 | $19.0M | $63.5M | ||
| Q1 24 | $20.3M | $82.3M |
| Q4 25 | $145.8M | $59.0M | ||
| Q3 25 | $140.0M | $26.5M | ||
| Q2 25 | $132.3M | $32.8M | ||
| Q1 25 | $130.9M | $33.8M | ||
| Q4 24 | $132.9M | $46.1M | ||
| Q3 24 | $140.0M | $65.5M | ||
| Q2 24 | $131.1M | $80.5M | ||
| Q1 24 | $132.4M | $96.2M |
| Q4 25 | $1.5B | $68.9M | ||
| Q3 25 | $1.5B | $54.2M | ||
| Q2 25 | $1.5B | $62.1M | ||
| Q1 25 | $1.5B | $77.7M | ||
| Q4 24 | $1.5B | $110.5M | ||
| Q3 24 | $1.5B | $135.2M | ||
| Q2 24 | $1.5B | $149.9M | ||
| Q1 24 | $1.5B | $167.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $16.0M | $-8.4M |
| Free Cash FlowOCF − Capex | $14.6M | — |
| FCF MarginFCF / Revenue | 111.9% | — |
| Capex IntensityCapex / Revenue | 10.4% | — |
| Cash ConversionOCF / Net Profit | 4.68× | -0.26× |
| TTM Free Cash FlowTrailing 4 quarters | $26.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.0M | $-8.4M | ||
| Q3 25 | $6.3M | $17.4M | ||
| Q2 25 | $4.8M | $-17.7M | ||
| Q1 25 | $2.2M | $-4.0M | ||
| Q4 24 | $14.8M | $-23.4M | ||
| Q3 24 | $2.9M | $12.8M | ||
| Q2 24 | $2.9M | $-18.7M | ||
| Q1 24 | $2.2M | $5.9M |
| Q4 25 | $14.6M | — | ||
| Q3 25 | $5.8M | — | ||
| Q2 25 | $4.2M | — | ||
| Q1 25 | $2.1M | — | ||
| Q4 24 | $14.3M | — | ||
| Q3 24 | $2.8M | — | ||
| Q2 24 | $2.8M | — | ||
| Q1 24 | $2.0M | — |
| Q4 25 | 111.9% | — | ||
| Q3 25 | 46.2% | — | ||
| Q2 25 | 35.6% | — | ||
| Q1 25 | 18.4% | — | ||
| Q4 24 | 129.3% | — | ||
| Q3 24 | 25.7% | — | ||
| Q2 24 | 26.2% | — | ||
| Q1 24 | 18.7% | — |
| Q4 25 | 10.4% | — | ||
| Q3 25 | 3.7% | — | ||
| Q2 25 | 5.3% | — | ||
| Q1 25 | 0.7% | — | ||
| Q4 24 | 4.2% | — | ||
| Q3 24 | 1.1% | — | ||
| Q2 24 | 1.1% | — | ||
| Q1 24 | 1.1% | — |
| Q4 25 | 4.68× | -0.26× | ||
| Q3 25 | 1.75× | — | ||
| Q2 25 | 1.86× | — | ||
| Q1 25 | 1.11× | — | ||
| Q4 24 | 5.96× | — | ||
| Q3 24 | 1.17× | — | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | 0.91× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
